Page last updated: 2024-12-05

phosphoribosyl pyrophosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phosphoribosyl pyrophosphate (PRPP) is a key intermediate in purine and pyrimidine nucleotide biosynthesis. It is synthesized from ribose 5-phosphate by the enzyme ribose phosphate pyrophosphokinase. PRPP is also a substrate for a number of other metabolic pathways, including the biosynthesis of histidine, tryptophan, and NAD+. PRPP is a highly reactive molecule and is therefore an important target for regulation of nucleotide biosynthesis. Deficiency in PRPP synthesis can lead to a variety of genetic disorders, including Lesch-Nyhan syndrome. PRPP is also an important target for drug development, as it is involved in the synthesis of many important metabolites. The synthesis of PRPP is highly regulated, with the enzyme ribose phosphate pyrophosphokinase being inhibited by high levels of PRPP. This regulation ensures that PRPP is only produced when it is needed.'

Phosphoribosyl Pyrophosphate: The key substance in the biosynthesis of histidine, tryptophan, and purine and pyrimidine nucleotides. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-phosphoribosyl diphosphate : A ribose diphosphate carrying an additional phosphate group at position 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

5-O-phosphono-alpha-D-ribofuranosyl diphosphate : A derivative of alpha-D-ribose having a phosphate group at the 5-position and a diphosphate at the 1-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7339
CHEBI ID17111
SCHEMBL ID187952
MeSH IDM0016716

Synonyms (71)

Synonym
5-o-phosphono-alpha-d-ribofuranosyl diphosphate
7540-64-9
prib-pp
alpha-phosphoribosylpyrophosphoric acid
5-o-phosphono-alpha-d-ribofuranose 1-(trihydrogen diphosphate)
phosphoribosyl pyrophosphate
CHEBI:17111
alpha-d-ribofuranose 5-(dihydrogen phosphate) 1-(trihydrogen diphosphate)
{[(2r,3s,4r,5r)-3,4-dihydroxy-5-{[hydroxy(phosphonooxy)phosphoryl]oxy}oxolan-2-yl]methoxy}phosphonic acid
phosphoribosyl pyrophosphate (prpp)
bdbm25315
1-o-pyrophosphono-5-o-phosphono-alpha-d-ribofuranose
phosphoribosylpyrophosphate
C00119
PRPP ,
5-phosphoribosyl diphosphate
5-phospho-alpha-d-ribose 1-diphosphate
DB01632
11ADFC3F-D4C1-4D39-ADD1-5FA85B9B3ED0
5-phosphorylribose 1-pyrophosphate
unii-w5555r4erg
w5555r4erg ,
alpha-d-ribofuranose, 5-(dihydrogen phosphate) 1-(trihydrogen diphosphate)
einecs 231-417-8
SCHEMBL187952
[(2r,3r,4s,5r)-3,4-dihydroxy-5-(phosphonooxymethyl)tetrahydrofuran-2-yl] phosphono hydrogen phosphate
.alpha.-d-ribofuranose, 5-(dihydrogen phosphate) 1-(trihydrogen diphosphate)
a-d-ribofuranose 5-phosphate 1-pyrophosphate
5-phospho-alpha-delta-ribose 1-diphosphate
alpha-delta-ribofuranose 5-phosphate 1-pyrophosphate
5-phosphoribosyl a-1-pyrophosphate
5-phospho-alpha-d-ribose-1-diphosphate
phosphoribosyl-pyrophosphate
5-phospho-alpha-d-riobse 1-diphosphate
phosphoribosyl-1-pyrophosphate
5-phosphorylribose 1-a-diphosphate
pp-ribose-p
phosphoribosylpyrophosphoric acid
alpha-d-5-phosphoribosyl 1-pyrophosphate
5-phospho-a-d-ribosyl pyrophosphate
a-d-5-(dihydrogen phosphate) 1-(trihydrogen pyrophosphate) ribofuranose
phosphoribosylpyrophosphorate
5-phosphorylribose 1-alpha-diphosphate
5-phosphorylribosyl 1-pyrophosphate
alpha-delta-5-phosphoribosyl 1-pyrophosphate
5-phosphoribose 1-pyrophosphate
5-phospho-alpha-d-ribosyl pyrophosphate
a-d-5-phosphoribosyl 1-pyrophosphate
5-phospho-a-d-ribose-1-diphosphate
alpha-delta-5-(dihydrogen phosphate) 1-(trihydrogen pyrophosphate) ribofuranose
alpha-d-5-(dihydrogen phosphate) 1-(trihydrogen pyrophosphate) ribofuranose
5-phospho-alpha-delta-ribosyl pyrophosphate
5-phospho-alpha-delta-ribose-1-diphosphate
a-d-ribofuranose, 5-(dihydrogen phosphate) 1-(trihydrogen diphosphate)
alpha-d-ribofuranose 5-phosphate 1-pyrophosphate
5-phosphoribosyl 1-diphosphate
1-o-[(r)-hydroxy(phosphonooxy)phosphoryl]-5-o-phosphono-alpha-d-ribofuranose
DTXSID40895038
Q420633
(2r,3r,4s,5r)-3,4-dihydroxy-5-((phosphonooxy)methyl)tetrahydrofuran-2-yl trihydrogen diphosphate
EN300-33060309
[({[(2r,3r,4s,5r)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]oxy}(hydroxy)phosphoryl)oxy]phosphonic acid
5-phosphoribosyl pyrophosphate
ribofuranose, 5-(dihydrogen phosphate) 1-(trihydrogen pyrophosphate), .alpha.-d-
.alpha.-d-ribofuranose, 5-phosphate 1-pyrophosphate
5-phospho-.alpha.-d-ribose-1-diphosphate
5-phosphoribosyl .alpha.-1-pyrophosphate
.alpha.-d-5-phosphoribosyl 1-pyrophosphate
5-phosphorylribose 1-.alpha.-diphosphate
(((2r,3s,4r,5r)-3,4-dihydroxy-5-((hydroxy(phosphonooxy)phosphoryl)oxy)oxolan-2-yl)methoxy)phosphonic acid
5-phospho-.alpha.-d-ribosyl pyrophosphate

Research Excerpts

Overview

Pris is a broadly conserved protein that synthesises 5-phosphoribosyl 1-pyrophospate (PRPP) Prs is a substrate for biosynthesis of at least 10 enzymatic pathways. These include the DNA building blocks purines and pyrimidines.

ExcerptReferenceRelevance
"Prs (phosphoribosyl pyrophosphate synthase) is a broadly conserved protein that synthesises 5-phosphoribosyl 1-pyrophospate (PRPP); a substrate for biosynthesis of at least 10 enzymatic pathways including biosynthesis of DNA building blocks - purines and pyrimidines. "( Reliable method for high quality His-tagged and untagged E. coli phosphoribosyl phosphate synthase (Prs) purification.
Glinkowska, MK; Szulc, A; Walter, BM, 2020
)
1.07

Compound-Compound Interactions

ExcerptReferenceRelevance
" We therefore studied its functional and metabolic effects in closed chest rats when given in combination with prazosin, verapamil or metoprolol, all of which have direct effects on the circulation."( Functional and metabolic effects of ribose in combination with prazosin, verapamil and metoprolol in rats in vivo.
Lortet, S; Zimmer, HG, 1989
)
0.28

Bioavailability

ExcerptReferenceRelevance
" It is concluded that Rib5P, generated in the oxidative segment of the PPP, is an important determinant of PPRibP synthesis in the lactating rat mammary gland and that insulin plays a central role in the regulation of the bioavailability of this precursor of nucleotide and nucleic acid synthesis."( Phosphoribosyl pyrophosphate and phosphoribosyl pyrophosphate synthetase in rat mammary gland. Changes in the lactation cycle and effects of diabetes, insulin and phenazine methosulphate.
Greenbaum, AL; Kunjara, S; McLean, P; Salih, N; Sochor, M, 1986
)
1.71
" Studies were designed to assess the bioavailability of 5-phosphoribosyl-1-pyrophosphate (PRPP) in the diabetic renal cortex because PRPP is an important determinant of the de novo synthesis of nucleotides."( Phosphoribosylpyrophosphate bioavailability in diabetic rat renal cortex in vivo.
Cortes, P; Levin, NW; Schoenberger, AM; Venkatachalam, KK; Verghese, CP, 1980
)
0.26
" The increase in the bioavailability of PPRibP, which is both a substrate and activator of the de novo and salvage pathways of purine and pyrimidine synthesis, is considered in relation to the increased nucleotide requirement associated with the rise in total hepatic RNA, DNA, and adenine nucleotide in the obese mouse."( Aspects of the regulation of hepatic phosphoribosyl pyrophosphate formation in the obese (ob/ob) mouse: relationship to the pentose phosphate pathway.
Greenbaum, AL; Kunjara, S; McLean, P; Sochor, M, 1993
)
0.56

Dosage Studied

ExcerptRelevanceReference
" A model established on the gene dosage effect, which likely results of these chromosome imbalances, may be proposed: (1) increase of thymidine kinase activity (chromosome 17q) and thus of the salvage pathway of thymidine synthesis (2) decrease of thymidine de novo pathways by decreased of thymidylate synthase (chromosome 18) and of dihydrofolate reductase (chromosome 5q) and thus accumulation of 2'-deoxyuridine-5'-P, which saves 2'-deoxycytidine 5'-P (3) decrease of cytidylate (or uridylate) kinase (chromosome 1p) and thus accumulation of 2-deoxycytidine-5-PP and of uridine-5-P (UMP) decreasing the metabolisation of orotidine-5'-P, precursor of 2-deoxycytidine-5-PP, which (4) saves -D-5-ribosyl-PP (PRPP) or even conversion of orotidine-5'-P in PRPP."( Induction of increased salvage pathways of nucleotide synthesis by dosage effect due to chromosome imbalances may be fundamental in carcinogenesis: the example of colorectal carcinoma.
Dutrillaux, B; Muleris, M, 1986
)
0.27
" Forty-eight hours after MTX dosage the level of 7-hydroxymethotrexate exceeded that of MTX by ten to one."( Methotrexate cytotoxicity: studies on its reversal by folates and nucleosides.
Lankelma, J; Leyva, A; Nederbragt, H; Pinedo, HM, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
5-O-phosphono-D-ribofuranosyl diphosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (95)

PathwayProteinsCompounds
Nicotinate and Nicotinamide Metabolism1434
Pyrimidine Metabolism2353
Glutamate Metabolism2244
Purine Metabolism3766
Pentose Phosphate Pathway1527
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency2244
Homocarnosinosis2244
Hyperinsulinism-Hyperammonemia Syndrome2244
Adenosine Deaminase Deficiency3766
Adenylosuccinate Lyase Deficiency3766
Gout or Kelley-Seegmiller Syndrome3766
Lesch-Nyhan Syndrome (LNS)3766
Molybdenum Cofactor Deficiency3766
Xanthine Dehydrogenase Deficiency (Xanthinuria)3766
Purine Nucleoside Phosphorylase Deficiency3766
AICA-Ribosiduria3766
beta-Ureidopropionase Deficiency2353
UMP Synthase Deficiency (Orotic Aciduria)2353
Dihydropyrimidinase Deficiency2353
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)2353
2-Hydroxyglutric Aciduria (D and L Form)2244
Azathioprine Action Pathway4782
Mercaptopurine Action Pathway4780
Thioguanine Action Pathway4781
Xanthinuria Type I3766
Xanthinuria Type II3766
Glucose-6-phosphate Dehydrogenase Deficiency1527
Ribose-5-phosphate Isomerase Deficiency1527
Transaldolase Deficiency1527
Adenine Phosphoribosyltransferase Deficiency (APRT)3766
Mitochondrial DNA Depletion Syndrome-33766
Myoadenylate Deaminase Deficiency3766
Succinic Semialdehyde Dehydrogenase Deficiency2244
Mercaptopurine Metabolism Pathway1524
Thioguanine Metabolism Pathway14
Histidine Biosynthesis821
NAD Biosynthesis520
NAD Salvage620
PRPP Biosynthesis38
Purine Nucleotides De Novo Biosynthesis2945
Secondary Metabolites: Histidine Biosynthesis820
Tryptophan Metabolism II623
Thiamin Diphosphate Biosynthesis1027
Purine Nucleotides De Novo Biosynthesis 22945
Adenine and Adenosine Salvage I412
Adenine and Adenosine Salvage III58
Guanine and Guanosine Salvage310
Purine Ribonucleosides Degradation717
NAD Metabolism1435
Nicotinate and Nicotinamide metabolism ( Nicotinate and Nicotinamide metabolism )2225
Nicotinamide D-ribonucleotide + Pyrophosphate = Nicotinamide + D-5-Phospho-ribosyl 1-diphosphate ( Nicotinate and Nicotinamide metabolism )14
Mitochondrial DNA Depletion Syndrome3566
5'-Orotidylic acid + Pyrophosphate = Orotic acid + D-5-Phospho-ribosyl 1-diphosphate ( Pyrimidine Nucleotides and Nucleosides metabolism )14
ATP + D-Ribose 5-phosphate = AMP + D-5-Phospho-ribosyl 1-diphosphate ( Pyrimidine Nucleotides and Nucleosides metabolism )34
Pentose phosphate cycle ( Pentose phosphate cycle )2225
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
AMP + Pyrophosphate = Adenine + D-5-Phospho-ribosyl 1-diphosphate ( Purine nucleotides and Nucleosides metabolism )14
IMP + Pyrophosphate = Hypoxanthine + D-5-Phospho-ribosyl 1-diphosphate ( Purine nucleotides and Nucleosides metabolism )14
5'-Phospho-ribosyl-4-carboxamido-5-amino-imidazole + Pyrophosphate = 5-Amino-4-imidazole-carboxyamide + D-5-Phospho-ribosyl 1-diphosphate ( Purine nucleotides and Nucleosides metabolism )14
XMP + Pyrophosphate = Xanthine + D-5-Phospho-ribosyl 1-diphosphate ( Purine nucleotides and Nucleosides metabolism )14
GMP + Pyrophosphate = Guanine + D-5-Phospho-ribosyl 1-diphosphate ( Purine nucleotides and Nucleosides metabolism )14
Pyrimidine Nucleotides and Nucleosides metabolism ( Pyrimidine Nucleotides and Nucleosides metabolism )4549
Biomarkers for pyrimidine metabolism disorders1432
Purine metabolism1336
NAD+ Signalling Pathway (Cancer)1012
NAD+ Signalling and Aging1110
Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics2719
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
Pyrimidine synthesis and deprivation pathway (COVID-19 Disease Maps)1329
NAD metabolism in oncogene-induced senescence and mitochondrial dysfunction-associated senescence19
NAD biosynthesis II (from tryptophan)024
uridine-5'-phosphate biosynthesis018
pyrimidine ribonucleotides de novo biosynthesis022
salvage pathways of purine nucleosides021
salvage pathways of adenine, hypoxanthine, and their nucleosides023
purine and pyrimidine metabolism032
purine nucleotides de novo biosynthesis I039
superpathway of histidine, purine, and pyrimidine biosynthesis064
purine nucleotides de novo biosynthesis II033
pyridine nucleotide cycling017
salvage pathways of guanine, xanthine, and their nucleosides017
salvage pathways of purine nucleosides I027
tryptophan degradation via kynurenine016
NAD biosynthesis (from tryptophan)020
superpathway of histidine, purine and pyrimidine biosynthesis031
NAD biosynthesis I from aspartate020
NAD salvage pathway I017
Histidine metabolism120
NAD biosynthesis II from tryptophan024
Biochemical pathways: part I0466
NAD+ metabolism014
Pyrimidine metabolism038
Purine metabolism and related disorders2353
Pyrimidine metabolism and related diseases1844
Histidine biosynthesis I721
Tryptophan biosynthesis216
De novo synthesis of UMP221

Research

Studies (636)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990410 (64.47)18.7374
1990's117 (18.40)18.2507
2000's61 (9.59)29.6817
2010's33 (5.19)24.3611
2020's15 (2.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.40 (24.57)
Research Supply Index6.49 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index77.13 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (0.92%)5.53%
Reviews51 (7.86%)6.00%
Case Studies17 (2.62%)4.05%
Observational0 (0.00%)0.25%
Other575 (88.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]